CArdioMetabolism and Atherosclerotic PlaqUe progreSsion
NCT ID: NCT05117424
Last Updated: 2024-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2017-01-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens
NCT07043166
Metabolomics Profiling of Coronary Heart Disease
NCT05138731
Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients
NCT00171548
Risk Factor Analysis for Developing Metabolic Syndrome in Korean Adults
NCT01594710
Metabolic Syndrome and Degenerate Meniscus Tears
NCT04837456
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Established coronary artery disease or metabolic disorders, including:
1. Type 2 diabetes diagnosed by one of the following criteria:
HbA1c \>/= 6.5% Fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT \>/= 11.1 mmol/l Already receiving glucose-lowering agents
2. Prediabetes
3. Obesity
4. Chronic kidney disease
5. Hyperuricemia
6. Dyslipidemia
Exclusion Criteria
* Severe anemia (hemoglobin \< 60g/L)
* Familial hypercholesterolemia
* Active malignant tumor
* Active autoimmune diseases on corticosteroids
* Acute or chronic infection
* Life expectancy \< 1 year
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
RUIYAN ZHANG
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lin Lu, M.D., Ph.D.
Role: STUDY_DIRECTOR
Ruijin Hospital, Shanghai Jiaotong School of Medicine
Fenghua Ding, M.D., Ph.D.
Role: STUDY_CHAIR
Ruijin Hospital, Shanghai Jiaotong School of Medicine
Ruiyan Zhang, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital, Shanghai Jiaotong School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RJH-CAMPUS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.